1331 related articles for article (PubMed ID: 24681664)
1. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
2. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
3. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
5. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
[TBL] [Abstract][Full Text] [Related]
6. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
7. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
10. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
11. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
12. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
[TBL] [Abstract][Full Text] [Related]
13. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
14. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
[TBL] [Abstract][Full Text] [Related]
15. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
[TBL] [Abstract][Full Text] [Related]
16. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
Villeneuve S; Rabinovici GD; Cohn-Sheehy BI; Madison C; Ayakta N; Ghosh PM; La Joie R; Arthur-Bentil SK; Vogel JW; Marks SM; Lehmann M; Rosen HJ; Reed B; Olichney J; Boxer AL; Miller BL; Borys E; Jin LW; Huang EJ; Grinberg LT; DeCarli C; Seeley WW; Jagust W
Brain; 2015 Jul; 138(Pt 7):2020-33. PubMed ID: 25953778
[TBL] [Abstract][Full Text] [Related]
17. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
[TBL] [Abstract][Full Text] [Related]
18. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
19. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
[TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.
Villemagne VL; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Hodges J; Harada R; Yates P; Piguet O; Pejoska S; Doré V; Yanai K; Masters CL; Kudo Y; Rowe CC; Okamura N
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):816-26. PubMed ID: 24514874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
